Isaac Melamed

2.2k total citations
51 papers, 1.4k citations indexed

About

Isaac Melamed is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Isaac Melamed has authored 51 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Immunology, 19 papers in Hematology and 15 papers in Genetics. Recurrent topics in Isaac Melamed's work include Immunodeficiency and Autoimmune Disorders (35 papers), Platelet Disorders and Treatments (16 papers) and Blood disorders and treatments (14 papers). Isaac Melamed is often cited by papers focused on Immunodeficiency and Autoimmune Disorders (35 papers), Platelet Disorders and Treatments (16 papers) and Blood disorders and treatments (14 papers). Isaac Melamed collaborates with scholars based in United States, Germany and Austria. Isaac Melamed's co-authors include Richard L. Wasserman, Mark R. Stein, Chaim M. Roifman, Heinz Leibl, Philip M. Sherman, Donald Y.M. Leung, Orathai Jirapongsananuruk, Stephen Feanny, Sudhir Gupta and David Gelmont and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Immunology and Biochemical and Biophysical Research Communications.

In The Last Decade

Isaac Melamed

50 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Isaac Melamed United States	20	795	511	321	150	138	51	1.4k
Christopher Brown United States	22	230 0.3×	382 0.7×	230 0.7×	77 0.5×	74 0.5×	40	1.8k
Esther Choi United States	23	266 0.3×	562 1.1×	125 0.4×	235 1.6×	95 0.7×	38	1.9k
Andrew L. Rankin United States	16	1.0k 1.3×	117 0.2×	97 0.3×	76 0.5×	456 3.3×	22	1.9k
Keiko Nomura Japan	20	258 0.3×	195 0.4×	96 0.3×	172 1.1×	56 0.4×	75	1.1k
John G. Gartner Canada	19	572 0.7×	293 0.6×	91 0.3×	45 0.3×	71 0.5×	52	1.5k
Richard D. Bagnall Australia	32	163 0.2×	788 1.5×	481 1.5×	154 1.0×	163 1.2×	79	3.3k
Kumaran Deiva France	27	259 0.3×	234 0.5×	386 1.2×	115 0.8×	81 0.6×	97	2.4k
Ian C. Chikanza United Kingdom	24	422 0.5×	177 0.3×	129 0.4×	38 0.3×	93 0.7×	49	1.7k
Elizabeth A. Sekul United States	13	188 0.2×	154 0.3×	166 0.5×	157 1.0×	130 0.9×	18	1.1k
Sarah Smithson United Kingdom	16	143 0.2×	180 0.4×	731 2.3×	82 0.5×	109 0.8×	55	1.5k

Countries citing papers authored by Isaac Melamed

Since Specialization

Citations

This map shows the geographic impact of Isaac Melamed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isaac Melamed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isaac Melamed more than expected).

Fields of papers citing papers by Isaac Melamed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isaac Melamed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isaac Melamed. The network helps show where Isaac Melamed may publish in the future.

Co-authorship network of co-authors of Isaac Melamed

This figure shows the co-authorship network connecting the top 25 collaborators of Isaac Melamed. A scholar is included among the top collaborators of Isaac Melamed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isaac Melamed. Isaac Melamed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gupta, Sudhir, Isaac Melamed, Jolán E. Walter, et al.. (2023). Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens. Journal of Clinical Immunology. 43(6). 1414–1425. 2 indexed citations

Kriván, Gergely, Michael Borte, Pere Soler‐Palacín, et al.. (2022). BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children. Journal of Clinical Immunology. 43(3). 557–567. 2 indexed citations

Melamed, Isaac, et al.. (2021). Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome. Journal of Child and Adolescent Psychopharmacology. 31(2). 118–128. 12 indexed citations

Melamed, Isaac, et al.. (2021). Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study. Frontiers in Immunology. 12. 632744–632744. 2 indexed citations

Kobayashi, Roger H., Sudhir Gupta, Isaac Melamed, et al.. (2019). Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies. Frontiers in Immunology. 10. 40–40. 15 indexed citations

Melamed, Isaac, et al.. (2019). Observational Study of Intravenous Immunoglobulin 5% for Alleviating Adverse Drug Reactions in Primary Immunodeficiency Disorders. Journal of Clinical & Cellular Immunology. 10(3). 1–6. 1 indexed citations

Borte, Michael, Isaac Melamed, Grażyna Pulka, et al.. (2017). Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. Journal of Clinical Immunology. 37(6). 603–612. 10 indexed citations

Wasserman, Richard L., Isaac Melamed, Mark R. Stein, et al.. (2016). Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. Journal of Clinical Immunology. 36(6). 571–582. 41 indexed citations

Melamed, Isaac, et al.. (2016). Neurologic manifestations of hereditary angioedema. Annals of Allergy Asthma & Immunology. 118(1). 119–120. 5 indexed citations

10.

Suez, Daniel, Mark R. Stein, Sudhir Gupta, et al.. (2016). Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America. Journal of Clinical Immunology. 36(7). 700–712. 48 indexed citations

11.

Wasserman, Richard L., Isaac Melamed, Michal Stein, et al.. (2012). Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD). 2 indexed citations

12.

Wasserman, Richard L., Isaac Melamed, Robert P. Nelson, et al.. (2011). Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency. Clinical Pharmacokinetics. 50(6). 405–414. 57 indexed citations

13.

Wasserman, Richard L., Isaac Melamed, Lisa Kobrynski, et al.. (2011). Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease. Journal of Clinical Immunology. 31(3). 323–331. 64 indexed citations

14.

Wasserman, Richard L., Joseph A. Church, Hans Peter, et al.. (2009). Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. European Journal of Pharmaceutical Sciences. 37(3-4). 272–278. 43 indexed citations

15.

Church, Joseph A., Heinz Leibl, Mark R. Stein, et al.. (2006). Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency. Journal of Clinical Immunology. 26(4). 388–395. 64 indexed citations

16.

Bar‐Or, David, Leonard T. Rael, Raphael Bar-Or, et al.. (2006). Severe systemic immune response syndrome, low plasma paraoxonase activity, and a new albumin species in a traumatized patient with Gaucher's disease. Clinica Chimica Acta. 374(1-2). 135–139. 2 indexed citations

17.

Melamed, Isaac, Richard A. Franklin, Chaya Brodie, et al.. (1996). Nerve growth factor signal transduction in human B lymphocytes is mediated by gp140^trk. European Journal of Immunology. 26(9). 1985–1992. 58 indexed citations

18.

Melamed, Isaac, Richard A. Franklin, & Erwin W. Gelfand. (1995). Microfilament Assembly Is Required for Anti-IgM Dependent Mapk and p90rsk Activation in Human B Lymphocytes. Biochemical and Biophysical Research Communications. 209(3). 1102–1110. 11 indexed citations

19.

Melamed, Isaac, Stephen Feanny, Philip M. Sherman, & Chaim M. Roifman. (1991). Benefit of ketotifen in patients with eosinophilic gastroenteritis. The American Journal of Medicine. 90(3). 310–314. 114 indexed citations

20.

Melamed, Isaac, Anne M. Griffiths, & Chaim M. Roifman. (1991). Benefit of oral immune globulin therapy in patients with immunodeficiency and chronic diarrhea. The Journal of Pediatrics. 119(3). 486–489. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact